The PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity [PTPN2i-MS-TCRseq]
To assess TCR diversity in AC484-treated tumors we profiled the TCRß chain repertoire from untreated, anti-PD-1-treated, or AC484-treated B16 tumours Overall design: We performed TCR profiling analysis on RNA extracted from subcutaneous B16 bulk tumor tissue to analyze the TCR repertoire upon AC484 treatment.